Exelon is a prescription medication used in the field of Neurology. Its active ingredient is rivastigmine, a reversible cholinesterase inhibitor that helps manage symptoms of certain dementias. Exelon is supplied as an oral pill in two strengths: 1.5 mg and 3 mg. In Hong Kong, Exelon is regulated by the Department of Health and is available only with a medical prescription. The brand is marketed by Novartis.
Rivastigmine inhibits the enzymes acetylcholinesterase and butyrylcholinesterase, which normally break down the neurotransmitter acetylcholine in the brain. By slowing this breakdown, rivastigmine increases the concentration of acetylcholine in synaptic clefts, enhancing cholinergic transmission. Improved cholinergic activity helps mitigate the cognitive decline and functional impairment seen in Alzheimer’s disease and Parkinson’s disease dementia. The medication is absorbed after oral ingestion, reaches peak plasma concentrations within 1-2 hours, and has a duration of action that supports once-daily dosing.
These indications are approved by Hong Kong’s Department of Health and are supported by clinical trials demonstrating cognitive benefits compared with placebo.
Exelon has been investigated for other neurodegenerative conditions, such as Lewy body dementia and vascular dementia. While some small studies suggest potential benefit, these uses are not approved by regulatory agencies in Hong Kong.
Disclaimer: Off-label use requires medical supervision and an individualized risk assessment.
If uncertain about suitability, patients should discuss their medical history with a healthcare professional.
These effects are usually dose-related and may lessen with gradual titration.
Any sign of these serious events warrants immediate medical attention.
Patients should provide a complete medication list, including over-the-counter drugs and herbal supplements, to their prescriber.
Standard dosing:
Begin with 1.5 mg once daily (preferably with breakfast).
After approximately four weeks, if the medication is well tolerated, the dose may be increased to 3 mg once daily.
Do not exceed the prescribed dose without consulting a healthcare provider.
Special population adjustments:
In patients with moderate liver impairment, clinicians may opt for a slower titration schedule.
For elderly patients, the 1.5 mg starting dose is recommended with careful monitoring.
Administration tips for the pill form:
Swallow the tablet whole; do not crush or chew.
Store at room temperature, away from moisture and direct sunlight.
Missed dose:
If a dose is missed and the next scheduled dose is more than 12 hours away, take the missed dose.
If it is close to the next dose, skip the missed one-do not double-dose.
Overdose:
Symptoms may include severe nausea, vomiting, profuse sweating, bronchospasm, and seizures.
Seek emergency medical care immediately; supportive care and monitoring are the primary treatments.
Discontinuation:
Abrupt cessation can lead to cholinergic withdrawal (e.g., nausea, vomiting).
A gradual taper under medical guidance is recommended.
Regular follow-up appointments allow clinicians to adjust dosing, manage side effects, and determine continued benefit.
This article provides educational information about Exelon and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Exelon should not be combined with other cholinesterase inhibitors (e.g., donepezil, galantamine) because this may cause excessive cholinergic effects. If a change in therapy is needed, a clinician will guide a safe transition.
Yes, provided the medication is kept in its original labeled container, accompanied by a copy of the prescription, and stored at room temperature. Check destination countries for any import restrictions on prescription drugs.
Cognitive benefits may become apparent after 4-6 weeks of consistent dosing, though individual responses vary. Continued assessment is essential to determine effectiveness.
Report persistent gastrointestinal symptoms to your healthcare provider. They may suggest taking the tablet with a larger meal, adjusting the dose, or prescribing an anti-emetic.
Both tablets contain the same inactive ingredients; the only difference is the amount of rivastigmine per tablet. They are interchangeable only under medical direction.
While not a primary effect, Exelon’s cholinergic activity can cause mild reductions in blood pressure, especially in patients prone to bradycardia. Monitoring is advised for those with existing hypotension.
No. Dose escalation to 3 mg is optional and depends on tolerability and therapeutic response. Some patients remain on the 1.5 mg dose if higher doses cause adverse effects.
Rivastigmine does not typically interfere with standard laboratory assays. However, liver function tests should be performed periodically as part of safety monitoring.
Exelon tablets are round, white (1.5 mg) or off-white (3 mg), and bear the imprint “EXELON 1.5” or “EXELON 3”. Appearance may vary slightly between manufacturers and regions.
